# Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients

> **NCT04341207** · PHASE2 · UNKNOWN · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 1000 (estimated)

## Conditions studied

- Cancer & COVID 19

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Azithromycin

## Key facts

- **NCT ID:** NCT04341207
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-03
- **Primary completion:** 2022-04
- **Final completion:** 2022-04
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04341207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04341207, "Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04341207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*